I-Mab (NASDAQ: IMAB), a clinical-stage biopharmaceutical company, has announced significant changes to its leadership structure. Wei Fu, currently the CEO of venture capital fund CBC Group and I-Mab’s founding shareholder, has been appointed as the chairman of the board. Fu succeeds Dr. Pamela M. Klein, who is stepping down from her role as interim chair.
Additionally, Raj Kannan will resign from his position as CEO and board member effective July 15, 2024. Dr. Sean Fu has been named as the interim CEO, a role he will undertake in addition to his current position as operating partner at ABio-X, a life sciences incubation platform based in Massachusetts.
Dr. Fu brings extensive experience to the role, having previously co-founded and served as CEO of RVAC Medicines, an mRNA platform company. He also held a senior vice-president role at China-based Luye Pharma, where he managed the company’s operations in the US, Germany, Switzerland, and Japan. Prior to these roles, Dr. Fu served as CEO of GeneLeap, a Luye subsidiary specializing in DNA and RNA therapeutics. His career also includes a 15-year tenure at Merck, Sharp & Dohme (NYSE: MSD), where he held various leadership positions in R&D, business development, finance, and operational management.
These leadership changes at I-Mab reflect a strategic realignment as the company navigates the evolving landscape of the biopharmaceutical industry. The appointments of Wei Fu and Dr. Sean Fu are expected to leverage their extensive industry experience and deep understanding of the market to steer the company towards future growth and success.- Flcube.com
